-
1
-
-
0041530262
-
The drug budget silo mentality in Europe: an overview
-
Garrison L., and Towse A. The drug budget silo mentality in Europe: an overview. Value in Health 6 Suppl. 1 (2003) 1-9
-
(2003)
Value in Health
, vol.6
, Issue.SUPPL. 1
, pp. 1-9
-
-
Garrison, L.1
Towse, A.2
-
2
-
-
23844484540
-
Cost-containment as part of pharmaceutical policy
-
Almarsdóttir A.B., and Traulsen J.M. Cost-containment as part of pharmaceutical policy. Pharmacy World & Science 27 3 (2005) 144-148
-
(2005)
Pharmacy World & Science
, vol.27
, Issue.3
, pp. 144-148
-
-
Almarsdóttir, A.B.1
Traulsen, J.M.2
-
3
-
-
0037239005
-
European healthcare policies for controlling drug expenditure
-
Ess S.M., Schneeweiss S., and Szucs T.D. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 21 2 (2003) 89-103
-
(2003)
Pharmacoeconomics
, vol.21
, Issue.2
, pp. 89-103
-
-
Ess, S.M.1
Schneeweiss, S.2
Szucs, T.D.3
-
4
-
-
34250736162
-
Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis
-
Garattini L., Cornago D., and Compadri P. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy 82 3 (2007) 330-339
-
(2007)
Health Policy
, vol.82
, Issue.3
, pp. 330-339
-
-
Garattini, L.1
Cornago, D.2
Compadri, P.3
-
5
-
-
33745011139
-
Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies
-
Art. No.: CD005979. doi:10.1002/14651858.CD005979
-
Aaserud M., Dahlgren A.T., Kösters J.P., Oxman A.D., Ramsay C., and Sturm H. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database of Systematic Reviews 2 (2006) Art. No.: CD005979. doi:10.1002/14651858.CD005979
-
(2006)
Cochrane Database of Systematic Reviews
, Issue.2
-
-
Aaserud, M.1
Dahlgren, A.T.2
Kösters, J.P.3
Oxman, A.D.4
Ramsay, C.5
Sturm, H.6
-
6
-
-
36348988465
-
International comparison of generic medicine prices
-
Simoens S. International comparison of generic medicine prices. Current Medical Research and Opinion 23 11 (2007) 2647-2654
-
(2007)
Current Medical Research and Opinion
, vol.23
, Issue.11
, pp. 2647-2654
-
-
Simoens, S.1
-
7
-
-
0036688443
-
Comparative approaches to pharmaceutical price regulation in the European Union
-
Mrazek M.F. Comparative approaches to pharmaceutical price regulation in the European Union. Croatian Medical Journal 43 4 (2002) 453-461
-
(2002)
Croatian Medical Journal
, vol.43
, Issue.4
, pp. 453-461
-
-
Mrazek, M.F.1
-
8
-
-
33847333167
-
Reference drug programs: effectiveness and policy implications
-
Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy 81 1 (2007) 17-28
-
(2007)
Health Policy
, vol.81
, Issue.1
, pp. 17-28
-
-
Schneeweiss, S.1
-
9
-
-
0031730424
-
Pharmaceutical reference prices. How do they work in practice?
-
Dickson M., and Redwood H. Pharmaceutical reference prices. How do they work in practice?. Pharmacoeconomics 14 5 (1998) 471-479
-
(1998)
Pharmacoeconomics
, vol.14
, Issue.5
, pp. 471-479
-
-
Dickson, M.1
Redwood, H.2
-
10
-
-
0036060499
-
Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes
-
Ioannides-Demos L.L., Ibrahim J.E., and McNeil J.J. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics 20 9 (2002) 577-591
-
(2002)
Pharmacoeconomics
, vol.20
, Issue.9
, pp. 577-591
-
-
Ioannides-Demos, L.L.1
Ibrahim, J.E.2
McNeil, J.J.3
-
11
-
-
0034680689
-
Review of the literature on reference pricing
-
López-Casasnovas G., and Puig-Junoy J. Review of the literature on reference pricing. Health Policy 54 2 (2000) 87-123
-
(2000)
Health Policy
, vol.54
, Issue.2
, pp. 87-123
-
-
López-Casasnovas, G.1
Puig-Junoy, J.2
-
12
-
-
0033065043
-
Outstanding regulatory aspects in the European pharmaceutical market
-
Kanavos P., and Mossialos E. Outstanding regulatory aspects in the European pharmaceutical market. Pharmacoeconomics 15 6 (1999) 519-533
-
(1999)
Pharmacoeconomics
, vol.15
, Issue.6
, pp. 519-533
-
-
Kanavos, P.1
Mossialos, E.2
-
13
-
-
35248832088
-
Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution
-
Gumbs P.D., Verschuren W.M., Souverein P.C., Mantel-Teeuwisse A.K., de Wit G.A., de Boer A., et al. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. British Journal of Clinical Pharmacology 64 5 (2007) 680-685
-
(2007)
British Journal of Clinical Pharmacology
, vol.64
, Issue.5
, pp. 680-685
-
-
Gumbs, P.D.1
Verschuren, W.M.2
Souverein, P.C.3
Mantel-Teeuwisse, A.K.4
de Wit, G.A.5
de Boer, A.6
-
14
-
-
2042503055
-
Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia
-
Morgan S.G., Agnew J.D., and Barer M.L. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia. Health Policy 68 3 (2004) 299-307
-
(2004)
Health Policy
, vol.68
, Issue.3
, pp. 299-307
-
-
Morgan, S.G.1
Agnew, J.D.2
Barer, M.L.3
-
15
-
-
0026600567
-
Norway's pivotal role in regulatory health economics and pharmaceutical cost containment - what can other countries learn?
-
Andersson F. Norway's pivotal role in regulatory health economics and pharmaceutical cost containment - what can other countries learn?. Health Policy 21 1 (1992) 17-34
-
(1992)
Health Policy
, vol.21
, Issue.1
, pp. 17-34
-
-
Andersson, F.1
-
16
-
-
0031974129
-
The impact of European harmonisation on Norwegian drug policy
-
Norris P. The impact of European harmonisation on Norwegian drug policy. Health Policy 43 1 (1998) 65-81
-
(1998)
Health Policy
, vol.43
, Issue.1
, pp. 65-81
-
-
Norris, P.1
-
17
-
-
27744457330
-
Deregulating the pharmacy market: the case of Iceland and Norway
-
Anell A. Deregulating the pharmacy market: the case of Iceland and Norway. Health Policy 75 1 (2005) 9-17
-
(2005)
Health Policy
, vol.75
, Issue.1
, pp. 9-17
-
-
Anell, A.1
-
18
-
-
67649188454
-
-
The Norwegian Association of Pharmaceutical Manufacturers, accessed 20.02.2008
-
The Norwegian Association of Pharmaceutical Manufacturers. Facts and figures. http://lmi.no/FullStory.aspx?m=146 [accessed 20.02.2008].
-
Facts and figures
-
-
-
19
-
-
63749102538
-
-
Patented Medicine Prices Review Board. Foreign price trends for patented medicines. PMPRB study series S-0216. Ontario; 2002.
-
Patented Medicine Prices Review Board. Foreign price trends for patented medicines. PMPRB study series S-0216. Ontario; 2002.
-
-
-
-
20
-
-
63749110255
-
-
Granum L. Economical effects of the reference price system. Report 04/1999. Oslo: The National Insurance Administration; 1999 [in Norwegian].
-
Granum L. Economical effects of the reference price system. Report 04/1999. Oslo: The National Insurance Administration; 1999 [in Norwegian].
-
-
-
-
21
-
-
63749121475
-
Evaluation of the reference price system
-
Report 44/. Oslo;, in Norwegian
-
Econ. Evaluation of the reference price system. Report 44/2000. Oslo; 2000 [in Norwegian].
-
(2000)
, pp. 2000
-
-
Econ1
-
22
-
-
0036967968
-
Pricing and reimbursement of pharmaceuticals in Norway
-
Hågå A., and Sverre J.M. Pricing and reimbursement of pharmaceuticals in Norway. The European Journal of Health Economics 3 3 (2002) 215-220
-
(2002)
The European Journal of Health Economics
, vol.3
, Issue.3
, pp. 215-220
-
-
Hågå, A.1
Sverre, J.M.2
-
23
-
-
63749086396
-
-
The Norwegian Medicines Agency, in Norwegian, accessed 29.09.2008
-
The Norwegian Medicines Agency. Reassessment of maximum PPP of prescription medicines [in Norwegian]. http://www.legemiddelverket.no/templates/InterPage_38821.aspx [accessed 29.09.2008].
-
Reassessment of maximum PPP of prescription medicines
-
-
-
24
-
-
63749124682
-
02-39: Lov om apotek (apotekloven)
-
LOV, in Norwegian, 2000
-
LOV 2000-06-02-39: Lov om apotek (apotekloven). Oslo: Ministry of Health and Care Services; 2000 [in Norwegian].
-
(2006)
Oslo: Ministry of Health and Care Services
-
-
-
25
-
-
14944362843
-
Evaluation of the pharmaceutical legislation and the index price system
-
Report 10/. Oslo;, in Norwegian
-
Econ. Evaluation of the pharmaceutical legislation and the index price system. Report 10/2004. Oslo; 2004 [in Norwegian].
-
(2004)
, pp. 2004
-
-
Econ1
-
26
-
-
63749120385
-
-
Dalen DM. The pharmaceutical market after the pharmacy reform. Regulation, market structure and competition. Skriftserie 11/2003. Oslo: Helseøkonomisk forskningsprogram; 2003 [in Norwegian].
-
Dalen DM. The pharmaceutical market after the pharmacy reform. Regulation, market structure and competition. Skriftserie 11/2003. Oslo: Helseøkonomisk forskningsprogram; 2003 [in Norwegian].
-
-
-
-
30
-
-
26044436000
-
Access to drugs: patent-drug price board to review guidelines
-
Sibbald B. Access to drugs: patent-drug price board to review guidelines. Canadian Medical Association Journal 172 9 (2005) 1169
-
(2005)
Canadian Medical Association Journal
, vol.172
, Issue.9
, pp. 1169
-
-
Sibbald, B.1
-
31
-
-
33749527199
-
A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences
-
Lexchin J. A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences. Health Policy 79 2-3 (2006) 214-220
-
(2006)
Health Policy
, vol.79
, Issue.2-3
, pp. 214-220
-
-
Lexchin, J.1
-
32
-
-
14944376871
-
The impact of price regulation on the launch delay of new drugs - evidence from twenty-five major markets in the 1990s
-
Danzon P.M., Wang Y.R., and Wang L. The impact of price regulation on the launch delay of new drugs - evidence from twenty-five major markets in the 1990s. Health Economics 14 3 (2005) 269-292
-
(2005)
Health Economics
, vol.14
, Issue.3
, pp. 269-292
-
-
Danzon, P.M.1
Wang, Y.R.2
Wang, L.3
-
33
-
-
0031943370
-
Pricing and reimbursement of pharmaceuticals. A new culture for the community pharmacist
-
Moen E., Toverud E.L., Grund J., and Brinchmann S. Pricing and reimbursement of pharmaceuticals. A new culture for the community pharmacist. Pharmacy World & Science 20 3 (1998) 107-112
-
(1998)
Pharmacy World & Science
, vol.20
, Issue.3
, pp. 107-112
-
-
Moen, E.1
Toverud, E.L.2
Grund, J.3
Brinchmann, S.4
-
34
-
-
0036435031
-
Pharmaceutical cost containment with reference-based pricing: time for refinements
-
Schneeweiss S., Maclure M., Dormuth C., and Avorn J. Pharmaceutical cost containment with reference-based pricing: time for refinements. Canadian Medical Association Journal 167 11 (2002) 1250-1251
-
(2002)
Canadian Medical Association Journal
, vol.167
, Issue.11
, pp. 1250-1251
-
-
Schneeweiss, S.1
Maclure, M.2
Dormuth, C.3
Avorn, J.4
-
35
-
-
33745956031
-
A re-examination of the impact of reference pricing on antihypertensive drug plan expenditures in British Columbia
-
Grootendorst P., and Stewart D. A re-examination of the impact of reference pricing on antihypertensive drug plan expenditures in British Columbia. Health Economics 15 7 (2006) 735-742
-
(2006)
Health Economics
, vol.15
, Issue.7
, pp. 735-742
-
-
Grootendorst, P.1
Stewart, D.2
|